🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Dollar Down, but Hits One-Month High Against Yen Over Rate Hike Bets

Published 04-01-2022, 07:38 am
© Reuters.
GBP/USD
-
USD/JPY
-
AUD/USD
-
NZD/USD
-
USD/CNY
-
PFE
-
DX
-
22UAy
-

By Gina Lee

Investing.com – The dollar was down on Tuesday morning in Asia but climbed to its strongest level in more than a month against the Japanese yen. A jump in U.S. Treasury yields overnight as investors bet on an early U.S. Federal Reserve interest rate hike also gave the U.S. currency a small boost.

The U.S. Dollar Index that tracks the greenback against a basket of other currencies inched down 0.04% to 96.180 by 8:52 PM ET (1:52 AM GMT).

The USD/JPY pair inched up 0.09% to 115.43.

The AUD/USD pair edged up 0.13% to 0.7200, with the Australian dollar near the near two-week low of $0.7184 hit during the previous session. The NZD/USD pair inched up 0.07% to 0.6789.

The USD/CNY pair was up 0.32% to 6.3727. Chinese data released earlier in the day showed that the Caixin manufacturing purchasing managers index for December was a better-than-expected 50.9.

The GBP/USD pair inched up 0.07% to 1.3481. The pound was flat from Monday, when it fell as low as $1.3431 for the first time since Nov. 29.

The Japanese, Chinese and Australian markets all re-opened after a holiday.

The dollar rose as high as 115.395 yen for the first time since Nov. 25, boosted by long-term U.S. Treasury yields soaring 12.5 basis points overnight to hit 1.6420% for the first time since Nov. 24.

Investors also continue to bet that the Fed will hike interest rates in 2022, with money markets fully pricing in a first hike by May and two more by the end of 2022.

"The market is pricing in a more aggressive U.S. rate hike scenario, or at least the risk thereof, in 2022, and that definitely remains the key support for the dollar," Barclays senior FX strategist Shinichiro Kadota told Reuters.

The number of global COVID-19 cases also continues to surge, thanks to the omicron variant. Global travel and public services continue to be delayed, with the surge also likely to delay the reopening of also some U.S. schools after the holidays.

However, investors remained hopeful that lockdowns could be avoided. Meanwhile, the U.S. Food and Drug Administration on Monday authorized a third dose of the Pfizer Inc. (NYSE:PFE)/ BioNTech SE (F:22UAy) COVID-19 vaccine for children aged between 12 and 15 years. The regulator also shortened the time for all booster shots to five months from six months after primary doses.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.